Solara Active Pharma Sciences Limited — Board Meeting, 25-07-2025: Outcome of Board Meeting

Solara Active Pharma Sciences' board has approved its Q1 FY26 consolidated financial results. Revenue surged 15% QoQ to ₹320.1 Cr, with Profit After Tax hitting ₹10.5 Cr, a 12-quarter high. The company appointed Rajesh Patro as Chief Risk Officer. Strategic focus remains on debt reduction, with gross debt down ₹143.3 Cr this quarter. The planned demerger of the CRAMS & Polymers business into a new entity, Synthix Global Pharma Solutions, is set to unlock value and strengthen the Legacy API business's balance sheet by transferring ₹200 Cr of debt.